Quick Answer
Aardvark Therapeutics, Inc. reported R&D Expense of $48.94 million for fiscal year 2025.
Aardvark Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $48.94M | +181.8% |
| 2024 | $17.36M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $13.74M | +237.9% | +4.5% |
| June 30, 2025 | $13.14M | +226.3% | +69.5% |
| March 31, 2025 | $7.75M | +542.5% | +90.8% |
| September 30, 2024 | $4.07M | — | +0.9% |
| June 30, 2024 | $4.03M | — | +233.8% |
| March 31, 2024 | $1.21M | — | — |
- Aardvark Therapeutics, Inc. showed an increase of +181.8% in R&D Expense compared to the prior fiscal year.
- Over the 2024–2025 period, Aardvark Therapeutics, Inc.’s r&d expense has grown by 181.8% (from $17.36 million to $48.94 million).
- The most recent figure is from Aardvark Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: